Dasatinib

Product NDC: 68001-661
11-digit product format: 680010661
Labeler code: 68001
Product ID: 68001-661_4c4a021d-a810-26d0-e063-6294a90abd2d
Type: HUMAN PRESCRIPTION DRUG
Nonproprietary name: dasatinib
Dosage form: TABLET, FILM COATED
Route: ORAL
Labeler: BluePoint Laboratories
Application: ANDA217217
Marketing category: ANDA
Marketing start: 2025-10-30
Substance: DASATINIB
Active strength: 50 mg/1
Pharmacologic classes: Cytochrome P450 3A4 Inhibitors [MoA], Kinase Inhibitor [EPC], Protein Kinase Inhibitors [MoA]
NDC exclude flag: No
Listing certified through: 2027-12-31
Current FDA listing: Yes

Source provenance: Browse the complete Orange Book source catalog · source snapshot 1.

Orange Book products#

Current product rows page 1 of 1 · 6 matching rows.

Application-product, Trade name, Ingredient table
Application-product	Trade name	Ingredient	Strength	Dosage form / route	TE codes	Approval date
A217217-001	DASATINIB	DASATINIB	20MG	TABLET / ORAL	AB	2025-03-03
A217217-002	DASATINIB	DASATINIB	50MG	TABLET / ORAL	AB	2025-03-03
A217217-003	DASATINIB	DASATINIB	70MG	TABLET / ORAL	AB	2025-03-03
A217217-004	DASATINIB	DASATINIB	80MG	TABLET / ORAL	AB	2025-03-03
A217217-005	DASATINIB	DASATINIB	100MG	TABLET / ORAL	AB	2025-03-03
A217217-006	DASATINIB	DASATINIB	140MG	TABLET / ORAL	AB	2025-03-03

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 6 matching rows.

Application-product, TE code table
Application-product	TE code
A217217-001	AB
A217217-002	AB
A217217-003	AB
A217217-004	AB
A217217-005	AB
A217217-006	AB

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
Captured	Edition	Application-product	Trade name	Strength	Dosage form / route	Product TE source text	Approval date	Source SHA-256
2026-02-19 14:30 UTC	2026-02	A217217-001	DASATINIB	20MG	TABLET / ORAL	AB	2025-03-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-002	DASATINIB	50MG	TABLET / ORAL	AB	2025-03-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-003	DASATINIB	70MG	TABLET / ORAL	AB	2025-03-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-004	DASATINIB	80MG	TABLET / ORAL	AB	2025-03-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-005	DASATINIB	100MG	TABLET / ORAL	AB	2025-03-03	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-006	DASATINIB	140MG	TABLET / ORAL	AB	2025-03-03	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-001	DASATINIB	20MG	TABLET / ORAL	AB	2025-03-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-002	DASATINIB	50MG	TABLET / ORAL	AB	2025-03-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-003	DASATINIB	70MG	TABLET / ORAL	AB	2025-03-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-004	DASATINIB	80MG	TABLET / ORAL	AB	2025-03-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-005	DASATINIB	100MG	TABLET / ORAL	AB	2025-03-03	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-006	DASATINIB	140MG	TABLET / ORAL	AB	2025-03-03	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A217217-001	DASATINIB	20MG	TABLET / ORAL	AB	2025-03-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-002	DASATINIB	50MG	TABLET / ORAL	AB	2025-03-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-003	DASATINIB	70MG	TABLET / ORAL	AB	2025-03-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-004	DASATINIB	80MG	TABLET / ORAL	AB	2025-03-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-005	DASATINIB	100MG	TABLET / ORAL	AB	2025-03-03	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-006	DASATINIB	140MG	TABLET / ORAL	AB	2025-03-03	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-001	DASATINIB	20MG	TABLET / ORAL	AB	2025-03-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-002	DASATINIB	50MG	TABLET / ORAL	AB	2025-03-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-003	DASATINIB	70MG	TABLET / ORAL	AB	2025-03-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-004	DASATINIB	80MG	TABLET / ORAL	AB	2025-03-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-005	DASATINIB	100MG	TABLET / ORAL	AB	2025-03-03	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-006	DASATINIB	140MG	TABLET / ORAL	AB	2025-03-03	`fd3edfee7708…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-001	DASATINIB	20MG	TABLET / ORAL	AB	2025-03-03	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-002	DASATINIB	50MG	TABLET / ORAL	AB	2025-03-03	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-003	DASATINIB	70MG	TABLET / ORAL	AB	2025-03-03	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-004	DASATINIB	80MG	TABLET / ORAL	AB	2025-03-03	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-005	DASATINIB	100MG	TABLET / ORAL	AB	2025-03-03	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-006	DASATINIB	140MG	TABLET / ORAL	AB	2025-03-03	`a50c72e98297…`

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
Captured	Edition	Application-product	TE code	Order	Source SHA-256
2026-02-19 14:30 UTC	2026-02	A217217-001	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-002	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-003	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-004	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-005	AB	1	`011fe1cb6892…`
2026-02-19 14:30 UTC	2026-02	A217217-006	AB	1	`011fe1cb6892…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-001	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-002	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-003	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-004	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-005	AB	1	`31067a03dcf5…`
2025-12-14 10:44 UTC · 2 captures of this ZIP	2025-12	A217217-006	AB	1	`31067a03dcf5…`
2025-08-23 18:47 UTC	2025-08	A217217-001	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-002	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-003	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-004	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-005	AB	1	`6a471c1ec25d…`
2025-08-23 18:47 UTC	2025-08	A217217-006	AB	1	`6a471c1ec25d…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-001	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-002	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-003	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-004	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-005	AB	1	`fd3edfee7708…`
2025-03-22 03:13 UTC · 3 captures of this ZIP	2025-03	A217217-006	AB	1	`fd3edfee7708…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-001	AB	1	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-002	AB	1	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-003	AB	1	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-004	AB	1	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-005	AB	1	`a50c72e98297…`
2026-07-26 02:55 UTC · 3 captures of this ZIP	2026-06	A217217-006	AB	1	`a50c72e98297…`

Additional Listing Data#

Finished product: Yes
Brand name base: Dasatinib
Listing expiration: 2027-12-31

Active Ingredients#

Ingredient, Strength table
Ingredient	Strength
DASATINIB	50 mg/1

Harmonized UNII identifiers#

UNII identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
RBZ1571X5H	Internal UNII lookup

Harmonized RxCUI identifiers#

RxCUI identifiers page 1 of 1 · 6 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
643105	Internal RxNorm lookup
643107	Internal RxNorm lookup
643109	Internal RxNorm lookup
799047	Internal RxNorm lookup
1045402	Internal RxNorm lookup
1045406	Internal RxNorm lookup

Harmonized SPL set identifiers#

SPL set identifiers page 1 of 1 · 1 matching rows.

Identifier, FDA.report destination table
Identifier	FDA.report destination
02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	Available on FDA.report

DailyMed Product Concepts#

Product concept, Relation, Version table
Product concept	Relation	Version	Effective
b66e60ef-563e-ddb8-43b4-d625943af44b	Product name	3	20251209
820d87d5-5779-4353-ae7e-33904df346a1	Product name	1	20241218
594e2c86-3079-4e6e-96c9-48f7a8afc78d	Product name	1	20230718

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDC	Product	Description	Form	Quantity	Strength	SPL version
68001-661-06	Dasatinib	60 in 1 BOTTLE	TABLET, FILM COATED	60		2

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDC	Billing unit	Product NDC	DailyMed indexing SPL	SPL version	Effective
68001-661-06	EA - Each	68001-661	503612f7-ebd7-46b0-bfbc-ccbb5ca9e096	1	2025-10-14

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 2 matching rows.

Brand, Generic, Manufacturer table
Brand	Generic	Manufacturer	SPL set ID	Effective date	Available safety fields	Join
Dasatinib	DASATINIB	BluePoint Laboratories	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2026-03-05	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 217217 application number: ANDA217217 ndc (product): 68001-661
Dasatinib	DASATINIB	Biocon Pharma Inc.	76e1833c-e105-5a3d-0f01-1330d8cc7ae1	2025-02-25	Warnings, Adverse reactions	Exact identifier application applno (ANDA): 217217 application number: ANDA217217

UNII, Preferred term, Registry number table
UNII	Preferred term	Registry number	Matched term
RBZ1571X5H	DASATINIB	863127-77-9	DASATINIB

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUI	RxNorm string	TTY	DailyMed	SPL version
799047	dasatinib 100 MG Oral Tablet	PSN	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
1045402	dasatinib 140 MG Oral Tablet	PSN	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
643105	dasatinib 20 MG Oral Tablet	PSN	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
643107	dasatinib 50 MG Oral Tablet	PSN	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
643109	dasatinib 70 MG Oral Tablet	PSN	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
1045406	dasatinib 80 MG Oral Tablet	PSN	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
799047	dasatinib 100 MG Oral Tablet	SCD	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
1045402	dasatinib 140 MG Oral Tablet	SCD	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
643105	dasatinib 20 MG Oral Tablet	SCD	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
643107	dasatinib 50 MG Oral Tablet	SCD	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
643109	dasatinib 70 MG Oral Tablet	SCD	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2
1045406	dasatinib 80 MG Oral Tablet	SCD	02b04c6f-4ea5-4fcb-bf6d-2631d5ab31e4	2

Packages#

Package NDC, 11-digit format, Description table
Package NDC	11-digit format	Description	Marketing start	Sample	Exclude flag	Status
68001-661-06	68001066106	60 TABLET, FILM COATED in 1 BOTTLE (68001-661-06)	2025-10-30	No	No	Current

Title, Manufacturer, Effective date table
Title	Manufacturer	Effective date	Type	Version
Dasatinib	BluePoint Laboratories \| Biocon Pharma Limited	2026-03-05	HUMAN PRESCRIPTION DRUG LABEL	2